Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERWON-EXT: Safety of Re-dosing IV Iron Isomaltoside in IDA
NCT02962648Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Pharmacosmos. Started Jan 2017; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02962648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962648.